A Study to Demonstrate the Benefit of a New Kind of Anti-cancer Treatment [PReferentially Expressed Antigen of MElanoma (PRAME) Immunotherapy] for Patients With Non-Small Cell Lung Cancer (NSCLC), After Removal of Their Tumor

Inclusion Criteria:

• The patient has radically resected NSCLC

• The NSCLC is of pathological stage IA-T1b, IB, II or IIIA NSCLC The surgical techniquefor resection of the patient's tumor is anatomical, involving at least a segmentectomyThe patient's tumor shows expression of PRAME.

• The patient is ≥ 18 years of age at the time of first consent.

• Written informed consent has been obtained from the patient prior to performance ofany study-specific procedure.

• The patient is free of disease (no residual tumor, no loco-regional recurrence, nodistant metastasis), as confirmed by a post- thoracic surgery contrast-enhancedcomputed tomography (CT scan) of the chest, upper abdomen and by a contrast-enhancedCT scan or Magnetic Resonance Imaging (MRI) of the brain. Other examinations should beperformed as clinically indicated.

• Eastern Co-operative Oncology Group (ECOG) performance status of 0, 1 or 2 at the timeof randomization

• Adequate bone-marrow reserve, adequate renal, hepatic and adrenal function as assessedby standard laboratory criteria

• If the patient is female, she must be of non-childbearing potential, i.e. have acurrent tubal ligation, hysterectomy, ovariectomy or be post-menopausalor if she is ofchildbearing potential, she must practice adequate contraceptionfor 30 days prior toadministration of study product, have a negative pregnancy test and continue suchprecautions during all study treatment period and for 2 months after last treatmentadministration.

• Patients who the investigator believes can and will comply with the requirements ofthis protocol (e.g. return for active follow-up visits).

Exclusion Criteria:

• The patient is diagnosed with a concomitant malignancy and/or has a history ofmalignancy within the past five years or has had a malignancy that has been incomplete remission for less than 5 years. Patients with effectively treated non -melanoma skin cancers or effectively treated carcinoma in situ of the cervix both ofwhich in remission for less than 5 years will be eligible.

• The patient has received any anti-cancer specific treatment, including radiotherapy,immunotherapy, hormonal therapy, chemotherapy or neo-adjuvant chemotherapy, exceptfor:

• Administration of adjuvant platinum-based doublet chemotherapy for the treatmentof the current NSCLC allowed between surgery and randomization.

• Treatment of previous malignancies as allowed by the protocol.

• The patient has been diagnosed with a Potential Immune-Mediated Disease (pIMD).Patients with vitiligo are not excluded from the study.

• The patient has a history of confirmed adrenal dysfunction.

• The patient requires concomitant treatment with any immunosuppressive agent, or withsystemic corticosteroids prescribed for chronic treatment (more than 7 consecutivedays).

• The patient needs chronic long term oxygen therapy (LTOT). The patient has medicallyuncontrolled congestive heart failure or hypertension, unstable heart disease oruncontrolled arrhythmia at the time of randomization.

• The patient has an uncontrolled bleeding disorder.

• The patient has undergone splenectomy.

• The patient is known to be Human Immunodeficiency Virus (HIV)-positive.

• The patient has psychiatric or addictive disorders that may compromise his/her abilityto give informed consent, or to comply with the trial procedures.

• The patient has other concurrent severe medical problems, unrelated to the malignancy,that would significantly limit full compliance with the study or expose the patient tounacceptable risk.

• The patient has a history of allergic disease or reactions likely to be exacerbated byany component of the study investigational product.

• The patient has received any investigational or non-registered product within the 30days preceding randomization, or planned use during the study period.

• For female patients: the patient is pregnant or lactating or is planning to becomepregnant.